New to aminoglycoside PK/PD? Learn the concepts → · See how it works →
Aminoglycoside Dosing
What is the indication for this course?
Regimen frequency
Not covered here: surgical prophylaxis (a single peri-operative dose, not therapeutic TDM) — this wizard is for therapeutic dosing and monitoring only.
Patient details
Enter age, sex, height, weight, and SCr to see IBW, AdjBW, BMI, dosing weight, and CrCl.
How should we dose this course?
Drug
NTM dosing here is amikacin-only (Harris Table 2 / 2020 ATS·ERS·ESCMID·IDSA) — locked to Amikacin.
Optional — sanity-check a stated target
Design the regimen, or fit it from measured levels
Full reasoning trace
Measured level
Level 1
Level 2
Full reasoning trace
Fits this patient's own clearance (CL) and volume of distribution (Vd) to the level(s) below by maximum a posteriori (MAP), starting from the population prior and shrinking toward it when levels are few or uninformative.
Measured levels
Full reasoning trace
CF-specific dosing is not yet supported — no dose is recommended here. Cystic fibrosis alters aminoglycoside PK (larger Vd, faster clearance) in ways this engine does not model, so no population default is shown in its place. Go back to Dose / Levels and enter measured level(s): individualized PK from real levels (Sawchuk-Zaske) doesn't depend on CF-specific population defaults, and will produce a real result here once computed.
Nothing computed yet — go back to Dose / Levels to design a starting regimen or enter measured level(s).
Starting regimen
No dose is computed for this result — see the full reasoning below.
Bayesian fit (individual CL/Vd)
- Clearance (CL)
- Volume (Vd)
- Ke / half-life
- AUC24 (steady state)
- Cmax/MIC · AUC24/MIC
The concentration-time curve needs a periodic dosing interval — not drawn for a one-time / redose-by-level regimen.
The reasoning
Aminoglycoside Dosing Expert
Patient & renal
Enter age, sex, height, weight, and SCr to see IBW, AdjBW, BMI, dosing weight, and CrCl.
Mode & results
Leave blank to use the engine's own indication-based default mg/kg.
Level 1
Level 2
Levels are ordered earliest-first automatically — enter them in either slot, whichever draw time is earlier is treated as the first (higher) level.
Fits this patient's own clearance (CL) and volume of distribution (Vd) to the level(s) below by maximum a posteriori (MAP). MIC is read from the patient block above.
Measured levels
Optional — sanity-check a stated target
Measured level assessment (MIC read from the patient block above)
CF-specific dosing is not yet supported — no dose is recommended here. Cystic fibrosis alters aminoglycoside PK (larger Vd, faster clearance) in ways this engine does not model, so no population default is shown in its place. You can still enter measured level(s) via the Two-level tab: individualized PK from real levels (Sawchuk-Zaske) doesn't depend on CF-specific population defaults.
Starting regimen
No dose is computed for this result — see the full reasoning below.
Bayesian fit (individual CL/Vd)
- Clearance (CL)
- Volume (Vd)
- Ke / half-life
- AUC24 (steady state)
- Cmax/MIC · AUC24/MIC
Concentration-time curve
The concentration-time curve needs a periodic dosing interval — not drawn for a one-time / redose-by-level regimen.
The reasoning